Research programme: paediatric malaria vaccine - Crucell/PRIBOMAL
Latest Information Update: 20 Jun 2011
At a glance
- Originator Crucell
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 20 Jun 2011 No development reported - Preclinical for Malaria in Netherlands (Parenteral)
- 30 Jan 2007 Preclinical trials in Malaria in Netherlands (Injection)